Castle Biosciences (CSTL) Operating Leases (2021 - 2026)

Castle Biosciences has disclosed Operating Leases across 6 years of filings, most recently posting $24.9 million for Q2 2026.

• In Q2 2026, Operating Leases fell 1.9% year-over-year to $24.9 million; the TTM figure through Jun 2026 stood at $24.9 million (down 1.9% YoY), while the FY2025 annual figure was $25.2 million, up 75.79% from the prior year.
• Operating Leases came in at $24.9 million for Q2 2026 at Castle Biosciences, down from $25.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $25.4 million in Q2 2025 to a low of $6.5 million in Q2 2022.
• Average Operating Leases over 5 years is $15.8 million, with a median of $14.0 million recorded in 2024.
• Year-over-year, Operating Leases surged 91.77% in 2023 and fell 1.9% in 2026.
• Over 5 years, Operating Leases stood at $11.5 million in 2022, then rose by 22.89% to $14.2 million in 2023, then grew by 1.21% to $14.3 million in 2024, then jumped by 75.79% to $25.2 million in 2025, then retreated by 1.28% to $24.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $24.9 million in Q2 2026, $25.1 million in Q1 2026, and $25.2 million in Q4 2025.